Long-acting lipoglycopeptide antibiotic
Dalbavancin
Brand names: Xydalba
Adult dose
Dose: 1500mg IV single dose OR 1000mg IV then 500mg IV after 7 days
Route: IV
Frequency: Single or 2-dose regimen
Clinical pearls
- Acute bacterial skin & soft tissue infections (ABSSSI) — gram-positive cover including MRSA
- BSAC OPAT guidance — ideal for facilitating early discharge
- Single-dose convenience valuable in homeless / IVDU populations
Contraindications
- Hypersensitivity to glycopeptides
Side effects
- Headache
- Nausea
- Diarrhoea
- Infusion reactions / red-man syndrome (rare)
- Hepatotoxicity
- C. difficile
Interactions
- Limited known
Monitoring
- LFTs
- C. difficile risk
- Infection response
Reference: BNF; BSAC OPAT; UKHSA AMR; SmPC; https://bnf.nice.org.uk/drugs/dalbavancin/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Corrected QT Interval (Bazett) · ECG
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Centor / McIsaac Score for Strep Pharyngitis · Throat
- FeverPAIN Score for Strep Throat · Throat
- Jarisch-Herxheimer Reaction Severity Assessment · Treatment Reactions
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023